NervGen to Advance NVG-291 as Potential Remyelination Therapy for MS

NervGen to Advance NVG-291 as Potential Remyelination Therapy for MS

Publication date: Jul 03, 2019

This post was originally published on this site NervGen wants to advance the development of NVG-291, its lead investigational therapy for spinal cord damage, as a potential remyelination treatment for multiple sclerosis (MS), the company announced. Following preclinical data showing that NVG-291 promotes myelin repair and regeneration of damaged nerves in animal models of spinal cord injury and MS, the compound has attracted pharma’s attention as a potential therapy for these and other neurodegenerative conditions. Blocking PTPσ with NVG-291 has been shown to promote regeneration of damaged nerves, improving nerve function in animal models for various medical conditions, according to NervGen. -As we advance our lead drug candidate, NVG-291, towards a Phase 1 clinical trial in Q1 2020 for spinal cord injury, we are leveraging the potential for our drug to also promote nerve remyelination as a therapy for MS,” Bill Radvak, NervGen’s executive chairman, said in a press release. The post NervGen to Advance NVG-291 as Potential Remyelination Therapy for MS appeared first on Multiple Sclerosis News Today.

Concepts Keywords
Cleveland Regenerative medicine
Clinical Trial ISP
FDA Nerve
Glial Scar Neuroregeneration
Heart Attack Neurology
IND Remyelination
Intracellular Neurophysiology
ISP Branches of biology
Molecule Nervous system
Multiple Sclerosis Organ systems
Myelin Scar
Nerve MS
Nerve Regeneration Investigational therapy
Nervous System
Neurodegenerative
Neurodegenerative Diseases
Oligodendrocyte
Peptide
Peripheral Nerve Injury
Pharma
PhD
Phosphatase
Pipeline
Proteases
Protein
Receptor
Regenerative Medicine
Spinal Cord
Spinal Cord Injury
Tyrosine
Western Reserve

Semantics

Type Source Name
disease MESH scarring
gene UNIPROT REG1A
gene UNIPROT SLC25A3
gene UNIPROT PTPRU
drug DRUGBANK L-Tyrosine
pathway BSID Spinal Cord Injury
disease DOID multiple sclerosis
disease MESH multiple sclerosis
gene UNIPROT SLC35G1
disease MESH development
gene UNIPROT MAGEE1
gene UNIPROT LARGE1
disease MESH community
gene UNIPROT RPS4X
disease MESH heart attack
disease DOID heart attack
pathway BSID Release
disease MESH Multiple
disease MESH neurodegenerative diseases
pathway BSID Neurodegenerative Diseases
drug DRUGBANK Silver
gene UNIPROT PDC
drug DRUGBANK Nonoxynol-9

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *